Connect with us

Spread & Containment

AbelsonTaylor: 2022

"What a year this is shaping up to be!” say leaders at AbelsonTaylor. “After last year’s amazing growth, we are still growing at a very healthy and…




433 W. Van Buren Street, Suite 650N, Chicago, IL 60607
312-894-5500 •




Account wins 8
Active business clients 22

Brands by 2021 sales

Brand-product accounts held 51
$25 million or less 3
$25 million-$50 million 9
$50 million-$100 million 10
$100 million-$500 million 6
$500 million-$1 billion 3
$1 billion or more 5
Products not yet approved/launched 13


Sales promotion 35%
Video brochures 35%
Broadcast 18%
Magazines 6%
Consumer publications 4%
Other 2%


Aerovate Therapeutics
Arcutis Biotherapeutics
Astellas Pharma US
City of Hope
CSL Behring
Fresenius Kabi
G1 Therapeutics
Kite Pharma
MetaMe Health
MMedx Group
Neurocrine Biosciences
Seres Therapeutics
Sunovion Pharmaceuticals
Takeda Pharmaceuticals North America


WINNER | Best Professional Web Campaign
There are 170,000 recurrences of C. difficile each year. Since C. diff is a dire condition and patients keep coming back, the idea of horror-movie sequels is a perfect fit.


Industry Person of the Year
Best Professional Web Campaign


“What a year this is shaping up to be!” say leaders at AbelsonTaylor. “After last year’s amazing growth, we are still growing at a very healthy and more sustainable rate. In 2021, we saw a 15 percent growth in revenue, eight big new business wins, 15 creative awards, 10 percent staff growth, new leadership for our diversity, equity, and inclusion priorities, strong organic growth from existing clients, the launch of eight new campaigns, and – most exciting – the creation of a new opportunity agency, ATNutrient, within the AbelsonTaylor Group.”

According to management, “All of this was accomplished despite the unprecedented staff churn that has impacted every agency, and most other businesses too. We are hiring from other companies, and they are hiring from us, and that makes it tough for everyone. But that’s the world we live in today. And after 40 years in business, we are still as strong as ever.”

Agency leaders say, “As we looked to the future and where we see the industry evolving, it was imperative that we rebrand to reflect our new focus on providing clients with breakthrough ideas that produce measurable, breakthrough results. So, we launched a new AbelsonTaylor identity and advertising campaign in 2021 – Return on Imagination (ROI). We also developed and launched a new creative evaluation tool to both assess and elevate concepts, with the goal of creating work that drives a deeper engagement and provides more measurable results for our clients’ brands.”

Recent Accomplishments

Examples of the agency’s breakthrough creative work on behalf of clients in 2021 includes campaigns for clients G1 Therapeutics, Pharmavite, Kite Pharma, CSL Behring, Neurocrine Biosciences, and Seres Therapeutics.

AbelsonTaylor began 2021 with a massive product launch with G1 Therapeutics for the Cosela brand. Both the HCP Spear the Tumor campaign and the patient-focused myeloprotection campaign launched with great success at Agency management says it was a fully virtual product launch because of the ongoing pandemic and the team made it one of the most successful launches in the history of AbelsonTaylor – due to excellent planning as well as strong client relationships and partnerships with the G1 Therapeutics brand team.

Pharmavite initiated a new campaign for Equelle focused on driving awareness of this non-prescription, hormone-free supplement which AT executives say is validated to provide menopause symptom relief. “We created the Equal Parts Science and Relief campaign focusing on the clinical evidence behind the Equelle brand,” agency managers say. The campaign can be found at

Additionally, the work with Pharmavite expanded to DTC campaigns for Equelle, including a social media launch on Instagram with Menopause, My Way.

In partnership with Kite Pharma, the AbelsonTaylor team developed the “Slayed the Dragon” patient campaign for Yescarta in follicular lymphoma and marginal zone lymphoma and continued to see success in driving patient demand. The campaign is at Additionally, the agency launched the Tecartus patient campaign to help raise awareness for this important brand in treating acute lymphocytic leukemia.

With Neurocrine Biosciences, the agency created a completely new DTC campaign – Spotlight – to help raise awareness of Ingrezza as an important treatment for tardive dyskinesia.

In partnership with Seres Therapeutics and Aimmune Therapeutics, AbelsonTaylor launched the “Endless Sequels” HCP campaign to raise awareness of the impact of recurrent C. difficile infection, at

And longtime client CSL Behring engaged with the agency to develop a campaign elevating awareness of advancements in hemophilia treatments through the science of transformative gene therapies, which can be found at

And it wasn’t just longstanding accounts that AbelsonTaylor found success with.

“With our new positioning and focus on driving business results for clients, our brand roster continued to grow in 2021,” management says. “We added an additional nine brands through business development and organic growth efforts.” New accounts included SER109 from Seres Therapeutics and Aimmune Therapeutics. The drug is a first-in-class investigational microbiome therapeutic for reducing the recurrence of C. difficile infection (CDI). Pharmavite gave the agency the opportunity to work on NatureMade Vitamins & Supplements as well as DTC campaign development for Equelle.

Other new accounts came in from Aerovate Therapeutics, which brought in AT to help with the first novel therapy in the company’s cardiopulmonary development program, an anti-proliferative therapy intended to address the root cause of pulmonary arterial hypertension (PAH). MiMedx hired the agency for consumer media on the Epifix wound-care brand

The agency was hired by Coherus Biosciences to launch a biosimilar candidate of reference product Lucentis (ranibizumab) within the ophthalmology market. Fresenius Kabi entrusted AT with the company’s global immunology biosimilars franchise and the U.S. launch of its biosimilars adalimumab and tocilizumab.

CooperSurgical expanded the agency’s work beyond the Endosee brand, awarding business for the Ally and Mara brands in the company’s women’s health division. CooperGenomics started to work with AT on its IVF genetic testing product.

Sunovion expanded AT’s work for the Latuda brand. And CSL Behring awarded the agency the global and U.S. launch of a therapy for hereditary angioedema

The agency also had a fruitful year for awards. “With 15 wins, we had quite a run on the awards circuit in 2021,” AT managers say.

Three campaigns brought in the majority of these wins. The Latuda “Real Expressions” commercial won two Telly Awards (one Gold and one Silver); five Communicator Awards (two Gold and three Silver); and an Rx Club Silver Award.

The Yescarta “More Than Hope” campaign picked up a PM360 Trailblazers Silver Award; a Communicator Silver Award; and four W3 Awards (one Gold and three Silvers) And the Jornay “Rising Star” campaign won the PM360 Greatest Creators Award.

The agency also marked continuing success in its DEI efforts. “We made significant progress last year in our continuing efforts to create a workplace where everyone feels welcome and able to grow in a safe and positive environment,” AT managers say. “We hired Yolanda Macias as our first director of Diversity and Inclusion, created a formal DEI mission, and identified five focus areas addressing Employee Centricity, Psychological Safety, Communication Systems, DEI Training and Awareness, and Diverse Representation. The agency also established a partnership with The Equality Institute.”

Future Plans

AbelsonTaylor headed into 2022 ever mindful of the toll the pandemic has taken on everyone, including our staff and their families,” agency leaders say. “The resilience they have shown has been truly remarkable. In 2022, we continue to apply the basic principles of therapeutics to our team – recover and thrive.”


Although the pandemic prevented our HeartsATWork program from doing many of the kinds of events that we’ve done in the past, we intensified our financial support of various organizations and found new ways of connecting with and supporting our communities,” agency managers say.

As food insecurity continues to be an issue for many in Chicago, with local food banks serving more people than ever before, AT continued to donate to the Greater Chicago Food Depository, “a group to whom we’ve contributed well over a million dollars during the course of our relationship,” agency leadership says.

AT also partnered with the Chicago Help Initiative and Lakeview Pantry, with employees volunteering their time to help deliver meals to those in need. And the agency continued a 20-plus year commitment to its partnership with Heifer International, particularly in support of the Future of Food project in Ecuador.

“In other activities, we leveraged our professional skills and extensive experience in rare diseases and women’s health to develop campaigns and content supporting Rare Disease Day and International Women’s Day,” management says. “We also held our first AT Olympics in the office, featuring some friendly competitive matches in things like ping pong and putting. While we gave out several gold medals, the real winner was the Special Olympics, to which we gave a generous donation. In October, we asked all employees to nominate charities that mean a lot to them, both to highlight the work the organizations do and to identify where and how we will provide support next year.”

(standing left to right) Keith Stenlund, executive VP/chief financial officer; Jody Van Swearingen, senior VP, creative director; Jeanine Koch, executive VP, project management; Eric Densmore, senior VP, account director; Jeff Berg, president; Dale Taylor, chairman/CEO
(seated left to right) Stephen Neale, executive VP, chief creative officer; Lynnette Hunter, executive VP, director of client services; Mark Finn, senior VP, account director; Tristen George, senior VP, creative director; Laura Bartmess, senior VP, account director


Read More

Continue Reading

Spread & Containment

Shedding light on reptilian health: Researchers investigate origins of snake fungal disease in U.S.

Although only recently recognized as an issue in wildlife ecology, snake fungal disease (SFD) is of emerging concern in the U.S., with parallels among…



Although only recently recognized as an issue in wildlife ecology, snake fungal disease (SFD) is of emerging concern in the U.S., with parallels among other better-known wildlife fungal diseases such as white-nose syndrome in bats. SFD can be deadly to snakes, and even in milder cases disrupts an animal’s abilities to perform normal biological functions such as hibernation, eating and avoiding predators.

Credit: Northern Arizona University

Although only recently recognized as an issue in wildlife ecology, snake fungal disease (SFD) is of emerging concern in the U.S., with parallels among other better-known wildlife fungal diseases such as white-nose syndrome in bats. SFD can be deadly to snakes, and even in milder cases disrupts an animal’s abilities to perform normal biological functions such as hibernation, eating and avoiding predators.

To better understand SFD, a team of researchers, including assistant professor Jason Ladner of Northern Arizona University’s Pathogen and Microbiome Institute, conducted a genetic study of the pathogen that was recently published in PLOS Biology, “The population genetics of the causative agent of snake fungal disease indicate recent introductions to the USA.”

Collaborating with study co-author Jeff Lorch of the U.S. Geological Survey (USGS) and other scientists from the USGS, Genencor Technology Center, the University of California-Riverside, Stetson University, the Institute of Zoology, the University of Kentucky and Holyoke Community College, Ladner’s goal was to determine whether SFD originated in the U.S. or was introduced from outside the country, which could provide a historical basis for how it emerged—and ultimately inform management of the disease. 

“Snake fungal disease first came to be recognized in the U.S. around 2008. There happened to be a well-studied population of rattlesnakes in Illinois that started coming down with some very severe fungal infections. People asked, ‘OK, what is this thing? Where is it? What’s going on? Is this a new emerging fungal pathogen or not?’ What they eventually found was that it was already almost everywhere, at least in the eastern half of the U.S.,” Ladner said. 

SFD, though seemingly not as deadly as other wildlife fungal diseases, is still a worrying threat to animals that represent an important part of the ecosystem. “We’re very concerned, not just about SFD’s effect to drive population declines, but also as a contributing factor amongst many other threats that snakes are already facing, like habitat destruction or over-collection for the pet trade,” Lorch said. 

Understanding wildlife diseases is critical, both in the context of ecosystem health and in their potential effects on humans. “I have a lot of interest in wildlife diseases, partially because wildlife serves as important reservoirs for diseases that could potentially emerge in humans; SARS-coronavirus-2 is a great example of that. If we want to be prepared for the next emerging infectious disease in humans, we need to better understand the pathogens currently circulating in wildlife populations which may have the potential to be transmitted to humans,” Ladner said. 

The study presented unique difficulties, however. “For snakes, there’s almost no long-term population trend data, especially when we compare snakes to an animal like bats, which have suffered from white-nose syndrome,” Lorch said. “In many states, historical data on bat populations exists because they’re not generally as difficult to monitor as some other types of wildlife.”

Snakes, in contrast, “are pretty secretive animals. They’re not something that you probably see on the landscape routinely, unless you’re looking for them,” Lorch explains. Without a large body of historical data on North American snake populations, “it makes it hard to say what snake populations were doing before SFD was noticed. Long-term trends are really difficult to decipher.”

Prior to beginning research, the team had two hypotheses on how the disease originated in the U.S. “One hypothesis was that the fungus that causes this disease may have been introduced only recently into the U.S. and then has been spreading within the past several decades, maybe 100 years. The alternative hypothesis was that this pathogen has been here for a long time and is essentially native to the U.S.; maybe it’s been here for thousands of years and has been co-evolving with these snake populations. In the latter case, maybe it seems to be emerging simply because we’re looking for it now. Or there’s been some type of environmental change, maybe something linked to climate change, that is leading to an increase in the number of cases even though this pathogen has been here all along,” Ladner said.

In order to track the disease’s evolution, Ladner and Lorch created a “family tree” for strains of the fungus that causes SFD found in the U.S. “One of the ways we could reconstruct the history of the disease was to look at the genetics of the pathogen to get an idea of how long it’s been here and how it’s changed over time,” Lorch said. 

Studying the genetics of SFD provided the team with a trail of breadcrumbs, revealing more about its history and throwing light on SFD cases in the U.S. “The reason that genomic data is useful for doing this is because each time this fungus replicates, grows and divides, the polymerase (the molecule that makes the new copy) sometimes makes mistakes. Those mistakes result in mutations. And then those mutations will be passed on through the generations. By looking at those different mutations in the population, we can understand how long certain lineages have existed and have some idea of how the different strains are related to each other. And that can tell us something about how long SFD has been here,” Ladner said. 

After taking samples from different SFD-affected snakes, the team performed genetic sequencing on 82 strains of the fungus. This included strains of SFD isolated from wild snakes in the U.S. and Europe, as well as captive snakes from three different continents. Based on the genetic similarities and differences among the strains, the team was able to partially reconstruct the evolutionary history of this fungus. “In the U.S., we found that there are several divergent lineages of this fungus circulating, but a lack of intermediates between these lineages, which would be expected if they originated in the U.S. Because of that, we think that there were likely multiple, somewhat recent introductions of this fungus to the U.S., and that an unsampled population, somewhere else in the world, acted as a source,” Ladner said.

This evidence allowed the team to form conclusions on how SFD arrived in America. “It suggests that this fungus was introduced to the United States through anthropogenic means—humans moving these snakes around. The most likely culprit is the trading of captive snakes as pets: the different clonal lineages that we see in the U.S., we also see represented in captive snake populations,” Ladner said. 

The study provides guidance for future management of SFD in the U.S., as well as a better understanding of how it was introduced. “If we had caught SFD being introduced very early on, then you can imagine trying to stop the spread of the disease in the U.S. and potentially even eradicate it. I think that’s unlikely at this point, given how widespread it is. However, I think it’s still helpful to better understand the mechanism for how SFD was introduced, as there’s still the potential for new introductions of diverse strains from these source populations. If we know that this fungus was introduced several times over the past several decades through the captive animal trade, then putting more restrictions and controls and testing animals in that process could be important for preventing further spread,” Ladner said. 

Though their work provides critical insight on SFD, its treatment and movement in the U.S., both scientists stress the need for further research. “What I’m hoping is that this study increases awareness of the disease. I think SFD warrants more of our attention,” Lorch said. 

More work needs to be done to assess the ecosystem, population and species effects of SFD. “The broader question of, ‘what is going to be the impact of this fungal pathogen on these snake populations?’ is a very open question and needs more research,” Ladner said.

About Northern Arizona University

Founded in 1899, Northern Arizona University is a higher-research institution providing exceptional educational opportunities and outcomes in Arizona and beyond. NAU delivers a student-centered experience to its nearly 30,000 students in Flagstaff, statewide and online through rigorous academic programs in a supportive, inclusive and diverse environment. As a community-engaged engine of opportunity, NAU powers social impact and economic mobility for the students and communities it serves. The university’s longstanding history of educating and partnering with diverse students and communities throughout Arizona is enhanced by its recent designation as a Hispanic-Serving Institution (HSI). Dedicated, world-renowned faculty and staff help ensure students achieve academic excellence, experience personal growth, have meaningful research and experiential learning opportunities and are positioned for personal and professional success. Located on the Colorado Plateau, in one of the highest-ranked college towns in the country, the NAU Flagstaff Mountain Campus is truly a jewel of the Southwest.

# # #



Read More

Continue Reading

Spread & Containment

China Suggests It Could Maintain ‘Zero COVID’ Policy For 5 Years

China Suggests It Could Maintain ‘Zero COVID’ Policy For 5 Years

Authored by Paul Joseph Watson via Summit News,

China has suggested it will…



China Suggests It Could Maintain 'Zero COVID' Policy For 5 Years

Authored by Paul Joseph Watson via Summit News,

China has suggested it will maintain its controversial ‘zero COVID’ policy for at least 5 years, eschewing natural immunity and guaranteeing repeated rounds of new lockdowns.

“In the next five years, Beijing will unremittingly grasp the normalization of epidemic prevention and control,” said a story published by Beijing Daily.

The article quoted Cai Qi, the Communist Party of China’s secretary in Beijing and a former mayor of the city, who said that ‘zero COVID’ approach would remain in place for 5 years.

After the story prompted alarm, reference to “five years” was removed from the piece and the hashtag related to it was censored by social media giant Weibo.

“Monday’s announcement and the subsequent amendment sparked anger and confusion among Beijing residents online,” reports the Guardian.

“Most commenters appeared unsurprised at the prospect of the system continuing for another half-decade, but few were supportive of the idea.”

Although western experts severely doubt official numbers coming out of China, Beijing claimed success in limiting COVID deaths by enforcing the policy throughout 2021.

However, this meant that China never achieved anything like herd immunity, and at one stage the Omicron variant caused more more coronavirus cases in Shanghai in four weeks than in the previous two years of the entire pandemic.

Back in May, World Health Organization Director General Tedros Adhanom Ghebreyesus suggested that China would be better off if it abandoned the policy, but Beijing refused to budge.

As we previously highlighted, the only way of enforcing a ‘zero COVID’ policy is via brutal authoritarianism.

In Shanghai, children were separated from their parents in quarantine facilities and others were left without urgent treatment like kidney dialysis.

Panic buying of food also became a common occurrence as the anger threatened to spill over into widespread civil unrest.

Former UK government COVID-19 advisor Neil Ferguson previously admitted that he thought “we couldn’t get away with” imposing Communist Chinese-style lockdowns in Europe because they were too draconian, and yet it happened anyway.

“It’s a communist one party state, we said. We couldn’t get away with it in Europe, we thought,” said Ferguson.

“And then Italy did it. And we realised we could,” he added.

*  *  *

Brand new merch now available! Get it at

In the age of mass Silicon Valley censorship It is crucial that we stay in touch. I need you to sign up for my free newsletter here. Support my sponsor – Turbo Force – a supercharged boost of clean energy without the comedown. Get early access, exclusive content and behinds the scenes stuff by following me on Locals.

Tyler Durden Tue, 06/28/2022 - 18:05

Read More

Continue Reading

Spread & Containment

No sign of major crude oil price decline any time soon

Bullish pressure on crude oil markets doesn’t seem to be easing Crude oil prices fell last week, notching their second weekly decline in the face of…




Bullish pressure on crude oil markets doesn’t seem to be easing

Crude oil prices fell last week, notching their second weekly decline in the face of concern that rising interest rates could push the global economy into recession.

Yet the future of crude oil still seems bullish to many. Spare capacity, or lack of it, is just one of the reasons.

The global surplus of crude production capacity in May was less than half the 2021 average, the U.S. Energy Information Administration (EIA) reported on Friday.

The EIA estimated that as of May, producers in nations not members of the Organization of Petroleum Exporting Countries (OPEC) had about 280,000 barrels per day (bpd) of surplus capacity, down sharply from 1.4 million bpd in 2021. It said 60 per cent of the May 2021 figure was from Russia, which is increasingly under sanctions related to its invasion of Ukraine.

The OPEC+ alliance of oil producers is running out of capacity to pump crude, and that includes its most significant member, Saudi Arabia, Nigerian Minister of State for Petroleum Resources Timipre Sylva told Bloomberg last week.

“Some people believe the prices to be a little bit on the high side and expect us to pump a little bit more, but at this moment there is really little additional capacity,” Sylva said in a briefing with reporters on Friday. “Even Saudi Arabia, Russia, of course, Russia, is out of the market now more or less.” Nigeria was also unable to fulfil its output obligations, added Sylva.

Recent COVID-19-related lockdowns in parts of China – the world’s largest crude importer – also played a significant role in the global oil dynamics. The lack of Chinese oil consumption due to the lockdowns helped keep the markets in a check – somewhat.

Oil prices haven’t peaked yet because Chinese demand has yet to return to normal, a United Arab Emirates official told a conference in Jordan early this month. “If we continue consuming, with the pace of consumption we have, we are nowhere near the peak because China is not back yet,” UAE Energy Minister Suhail Al-Mazrouei said. “China will come with more consumption.”

Al-Mazrouei warned that without more investment across the globe, OPEC and its allies can’t guarantee sufficient supplies of oil as demand fully recovers from the pandemic.

But the check on the Chinese crude consumption seems to be easing.

On Saturday, Beijing, a city of 21 million-plus people, announced that primary and secondary schools would resume in-person classes. And as life seemed to return to normal, the Universal Beijing Resort, which was closed for nearly two months, reopened on Saturday.

Chinese economic hub Shanghai, with a population of 28 million-plus people, also declared victory over COVID after reporting zero new local cases for the first time in two months.

The two major cities were among several places in China that implemented curbs to stop the spread of the omicron wave from March to May.

But the easing of sanctions should mean oil’s price trajectory will resume its upward march.

In the meantime, in the U.S., the Biden administration is eying tougher anti-smog requirements. According to Bloomberg, that could negatively impact drilling across parts of the Permian Basin, which straddles Texas and New Mexico and is the world’s biggest oil field.

While the world is looking for clues about what the loss of supply from Russia will mean, reports are pouring in that the ongoing political turmoil in Libya could plague its oil output throughout the year.

The return of blockades on oilfields and export terminals amid renewed political tension is depriving the market of some of Libya’s oil at a time of tight global supply, said Tsvetana Paraskova in a piece for

And in the ongoing political push to strangle Russian energy output, the G7 was reportedly discussing a price cap on oil imports from Russia. Western countries are increasingly frustrated that their efforts to squeeze out Russian energy supplies from the markets have had the counterproductive effect of driving up the global crude price, which is leading to Russia earning more money for its war chest.

To tackle the issue, and increase pressure on Russia, U.S. Treasury Secretary Janet Yellen is proposing a price cap on Russian crude oil sales. The idea is to lift the sanction on insurance for Russian crude cargo for countries that accept buying Russian oil at an agreed maximum price. Her proposal is aimed at squeezing Russian crude out of the market as much as possible.

So the bullish pressure on crude oil markets doesn’t seem to be easing.

By Rashid Husain Syed

Toronto-based Rashid Husain Syed is a respected energy and political analyst. The Middle East is his area of focus. As well as writing for major local and global newspapers, Rashid is also a regular speaker at major international conferences. He has provided his perspective on global energy issues to the Department of Energy in Washington and the International Energy Agency in Paris.

Courtesy of Troy Media

Read More

Continue Reading